MURA (Mural Oncology) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mural Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5.56 Mil. Mural Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2.46 Mil. Mural Oncology's annualized Revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

Mural Oncology Debt-to-Revenue Historical Data

The historical data trend for Mural Oncology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Debt-to-Revenue Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

N/A

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial							N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Mural Oncology's Debt-to-Revenue

For the Biotechnology subindustry, Mural Oncology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mural Oncology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Mural Oncology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mural Oncology's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.56	+	2.462)	/	N/A
	=	N/A

Mural Oncology's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.56	+	2.462)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Mural Oncology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.